{ "meta": { "data_length": 1, "message": "Statement id stmt:ema:blincyto:1:0 retrieved successfully", "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Aema%3Ablincyto%3A1%3A0", "status": "success", "status_code": 200, "timestamp_elapsed": 0.002017, "timestamp_received": "2026-10-16T23:36:10.064736+00:00Z", "timestamp_returned": "2026-10-16T23:36:10.066753+00:00Z", "trace_id": "1c49af78-4fad-49e0-a302-aa8ba048407c" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:ema:blincyto:1:0", "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of adult patients with Philadelphia chromosome negative CD19 positive B-cell precusor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-20:0", "type": "Contribution", "description": "Adding EMA approvals for use to database", "date": "2024-10-20", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:ema:2019-01-18:0", "type": "Contribution", "description": "Indication received approval from the European Commission.", "date": "2019-01-18", "contributor": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." } } ], "reportedIn": [ { "id": "doc:ema:blincyto", "type": "Document", "documentType": "Regulatory approval", "name": "Blincyto (blinatumomab) [product information]. EMA.", "title": null, "aliases": [], "description": "Amgen Europe B.V. Blincyto (blinatumomab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "urls": [ "https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." }, "description": "The organization that published this document." }, { "name": "company", "value": "Amgen Europe B.V.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Blincyto", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "blinatumomab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2015-12-07", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-07-23", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:46", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:ncit:C3167", "conceptType": "Disease", "name": "Acute Lymphoblastic Leukemia", "mappings": [ { "relation": "narrowMatch", "coding": { "id": "coding:oncotree:BLL", "code": "BLL", "name": "B-Lymphoblastic Leukemia/Lymphoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2025_10_03", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=B-Lymphoblastic+Leukemia%2FLymphoma+%28BLL%29" ] } }, { "relation": "narrowMatch", "coding": { "id": "coding:oncotree:TLL", "code": "TLL", "name": "T-Lymphoblastic Leukemia/Lymphoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2025_10_03", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=T-Lymphoblastic+Leukemia%2FLymphoma+%28TLL%29" ] } } ], "extensions": [ { "name": "solid_tumor", "value": false, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:ncit:C3167", "code": "C3167", "name": "Acute Lymphoblastic Leukemia", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3167" ] } }, "objectTherapeutic": { "id": "tx:ncit:C62528", "conceptType": "Therapy", "name": "Blinatumomab", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1597258", "code": "1597258", "name": "blinatumomab", "system": "RxNorm", "systemVersion": "20250602", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1597258" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:45892531", "code": "45892531", "name": "blinatumomab", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/45892531" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "CD19 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C62528", "code": "C62528", "name": "Blinatumomab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62528" ] } }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:14", "present": true, "subject": { "id": "bmkr:14", "type": "CategoricalVariant", "name": "CD19 +", "constraints": [], "extensions": [ { "name": "biomarker_type", "value": "Protein expression" }, { "name": "marker", "value": "CD19" }, { "name": "unit", "value": "status" }, { "name": "equality", "value": "=" }, { "name": "value", "value": "Positive" } ] } }, { "id": "bmkr.criterion:15", "present": false, "subject": { "id": "bmkr:12", "type": "CategoricalVariant", "name": "BCR::ABL1", "constraints": [ { "type": "AdjacencyConstraint", "orderKnown": true, "adjoinedElements": [ { "id": "gene:hgnc:1014", "conceptType": "Gene", "name": "BCR", "primaryCoding": { "id": "coding:hgnc:1014", "code": "HGNC:1014", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000186716", "code": "ENSG00000186716", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000186716" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:613", "code": "613", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/613" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_004327.4", "code": "NM_004327.4", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4" ] } } ] }, { "id": "gene:hgnc:76", "conceptType": "Gene", "name": "ABL1", "primaryCoding": { "id": "coding:hgnc:76", "code": "HGNC:76", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000097007", "code": "ENSG00000097007", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000097007" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:25", "code": "25", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/25" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_005157.6", "code": "NM_005157.6", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6" ] } } ] } ] } ], "extensions": [ { "name": "biomarker_type", "value": "Gene fusion" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:ema:blincyto:1", "type": "Indication", "description": "BLINCYTO is indicated as monotherapy for the treatment of adults with Philadelphia chromosome-negative CD19 positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-20:0", "type": "Contribution", "description": "Adding EMA approvals for use to database", "date": "2024-10-20", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:ema:2019-01-18:0", "type": "Contribution", "description": "Indication received approval from the European Commission.", "date": "2019-01-18", "contributor": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." } } ], "reportedIn": [ { "id": "doc:ema:blincyto", "type": "Document", "documentType": "Regulatory approval", "name": "Blincyto (blinatumomab) [product information]. EMA.", "title": null, "aliases": [], "description": "Amgen Europe B.V. Blincyto (blinatumomab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "urls": [ "https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." }, "description": "The organization that published this document." }, { "name": "company", "value": "Amgen Europe B.V.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Blincyto", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "blinatumomab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2015-12-07", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-07-23", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }